Atypical behavioural effects of lorazepam: clues to the design of novel therapies?
- PMID: 20138190
- DOI: 10.1016/j.pharmthera.2010.01.004
Atypical behavioural effects of lorazepam: clues to the design of novel therapies?
Abstract
Aside from their pharmacokinetic properties, e.g. their speed of action and the duration of residual effects, benzodiazepines are still considered as equivalent in terms of their effects on cognition. Here we review evidence suggesting that certain benzodiazepines, especially lorazepam, differ in a number of respects, in particular with respect to their effects on cognition. We focus this review on memory, attention and visual perception, where impairments may be brought about by only a subset of benzodiazepines in spite of their administration at doses inducing similar sedative effects. This precludes an explanation in terms of sedation. Differences in the effects of benzodiazepines have also been found in electrophysiological and animal behavioural studies. These studies are important for therapeutic approaches for two reasons: first, effects of benzodiazepine prescription on cognitive functions will differ according to the benzodiazepine, contrary to what is usually believed. Less straightforwardly are the possible therapeutic implications of specific effects on cognition following treatment with lorazepam. Indeed, the specific effects this drug has on cognition may reveal not only side-effects but also effects of potential therapeutic value. Current research concentrates on a fine scale analysis of the effects of GABA on different sub-types of GABA(A) receptors. We suggest that from looking at what makes lorazepam different in a behavioural sense from other benzodiazepines we may be in a position to design innovative treatments for major aspects of complex disorders, including schizophrenia.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.J Psychopharmacol. 2009 Aug;23(6):625-32. doi: 10.1177/0269881108092595. Epub 2008 Jul 17. J Psychopharmacol. 2009. PMID: 18635696 Clinical Trial.
-
The effects of benzodiazepines on cognition.J Clin Psychiatry. 2005;66 Suppl 2:9-13. J Clin Psychiatry. 2005. PMID: 15762814 Review.
-
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.J Psychopharmacol. 2007 Jun;21(4):374-83. doi: 10.1177/0269881106072343. Epub 2006 Nov 8. J Psychopharmacol. 2007. PMID: 17092968 Clinical Trial.
-
Effects of single doses of alpidem, lorazepam, and placebo on memory and attention in healthy young and elderly volunteers.Pharmacopsychiatry. 1990 May;23 Suppl 3:114-9. doi: 10.1055/s-2007-1014546. Pharmacopsychiatry. 1990. PMID: 1974070 Clinical Trial.
-
Effects of valium and librium on human psychomotor and cognitive functions.Genet Psychol Monogr. 1984 May;109(2D Half):167-97. Genet Psychol Monogr. 1984. PMID: 6329901 Review.
Cited by
-
Anti-intrusion effect of Lorazepam: an experimental study.Psychiatry Investig. 2013 Sep;10(3):273-80. doi: 10.4306/pi.2013.10.3.273. Epub 2013 Sep 16. Psychiatry Investig. 2013. PMID: 24302951 Free PMC article.
-
Imagined motor action and eye movements in schizophrenia.Front Psychol. 2013 Jul 12;4:426. doi: 10.3389/fpsyg.2013.00426. eCollection 2013. Front Psychol. 2013. PMID: 23874317 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical